ArticleAdvances in therapy2026
Real-World Effectiveness and Safety of Advanced Combination Treatment in Patients with Refractory Inflammatory Bowel Disease.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdvanced combination treatment (ACT) pairs two advanced therapies with distinct mechanisms of action for inflammatory bowel disease (IBD) that has not responded to single agents. However, real-world evidence on individual regimens remains limited.
methodsWe retrospectively identified all ACT courses at a tertiary centre in Abu Dhabi (June 2021 to May 2026). A course required the concurrent use of two advanced therapies with documented clinical intent, with no minimum duration. Disease activity, laboratory values, endoscopic findings and therapeutic drug monitoring were recorded prospectively in the centre's IBD registry, and every rate is reported over the whole cohort. The primary outcome was composite remission (clinical and biochemical remission together); endoscopic outcomes were reported separately.
resultsA total of 16 patients (11 Crohn's disease, 5 ulcerative colitis) received 21 courses across 12 regimens; 13 (81%) were Emirati. The commonest combinations paired a selective anti-interleukin-23 agent with a Janus kinase inhibitor (10 courses) or with an anti-tumour necrosis factor agent (5). Patients had failed a median of four prior advanced therapies, and the median course duration was 218 days. Composite remission was achieved in 11 of 21 courses (52%, 95% confidence interval [CI] 30-74%; 11 of 16 patients), clinical remission in 15 of 21 (71%) and biochemical remission in 11 of 21 (52%); 14 of 21 (67%) were corticosteroid-free. Clinically timed endoscopic reassessment in 14 courses showed endoscopic remission in five. Twelve courses (57%) were discontinued, seven for treatment failure. One serious adverse event, a urinary tract infection requiring admission, occurred during combination therapy.
conclusionACT achieved composite remission in just over half of courses in this multi-refractory cohort, with one serious adverse event. These findings support consideration of ACT in carefully selected multi-refractory patients under close monitoring; further real-world data on individual regimens are needed to guide the choice of combination.
Indexed as
Identifiers
42879110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.